CNTX
Context Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.36
−0.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 4.1K | — | — | — | — |
| Gross Profit | (4.1K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 40.1M | 31.9M | 22.7M | 17.8M | 7.1M |
| SG&A Expense | 8.6M | 7.8M | 7.2M | 7.3M | 7.8M |
| General & Admin Expense | 8.6M | 7.8M | 7.2M | 7.3M | 7.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 500.0K |
| Total Operating Expenses | 48.7M | 39.7M | 29.9M | 25.1M | 15.4M |
| Cost and Expenses | 48.7M | 39.7M | 29.9M | 25.1M | 15.4M |
| Operating Income (EBIT) | (48.7M) | (39.7M) | (29.9M) | (25.1M) | (15.4M) |
| Non-Operating | |||||
| Interest Income | 2.5M | 3.4M | 3.2M | 1.2M | 547.3K |
| Interest Expense | — | — | — | — | 547.3K |
| Net Interest Income | 2.5M | 3.4M | 3.2M | 1.2M | — |
| Other Non-Op Income/Expense | 2.8M | 3.6M | 3.2M | 1.1M | 545.3K |
| Non-Operating Income (excl Interest) | (2.8M) | (3.6M) | (3.2M) | (1.1M) | (500.0K) |
| EBT (Pre-Tax Income) | (46.0M) | (36.1M) | (26.7M) | (24.0M) | (14.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (46.0M) | (36.1M) | (26.7M) | (24.0M) | (14.8M) |
| Earnings from Cont. Ops | (46.0M) | (36.1M) | (26.7M) | (24.0M) | (14.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (46.0M) | (36.1M) | (26.7M) | (24.0M) | (14.8M) |
| Per Share | |||||
| Basic EPS | ($0.48) | ($0.38) | ($0.46) | ($1.50) | ($0.93) |
| Diluted EPS | ($0.48) | ($0.38) | ($0.46) | ($1.50) | ($0.93) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 95.2M | 95.2M | 58.4M | 16.0M | 16.0M |
| Diluted Shares Outstanding | 95.2M | 95.2M | 58.4M | 16.0M | 16.0M |
| Profitability Metrics | |||||
| EBITDA | (45.9M) | (36.1M) | (26.7M) | (24.0M) | (14.9M) |
| D&A | 44.2K | 16.3K | 10.9K | 12.0K | 9.3K |
| EBIT | (46.0M) | (36.1M) | (26.7M) | (24.0M) | (14.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026